

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

PRESS RELEASE
For immediate release

AETERNA ZENTARIS REPORTS 2006 SECOND QUARTER RESULTS

QUARTER MARKED BY SEVERAL SIGNIFICANT ADVANCEMENTS IN PIPELINE

ALL AMOUNTS ARE IN U.S. DOLLARS

QUEBEC CITY, CANADA, AUGUST 11, 2006 -- AETerna Zentaris Inc. (TSX: AEZ; NASDAQ: AEZS) today reported financial and operating results for the second quarter ended June 30, 2006.

"During the second quarter, we made great strides in advancing our products through the pipeline at all stages as exemplified by Cetrotide(R)'s marketing approval in Japan, our successful meeting with the FDA leading to the upcoming filing of an IND to move forward into Phase 3 clinical development of cetorelix in benign prostatic hyperplasia (BPH), as well as the disclosure of positive clinical results in cancer with perifosine and AN-152. Most recently, we disclosed positive Phase 2 results for ozarelix in prostate cancer which will enable us to pursue further clinical trials in this indication. Additionally, we signed a license and collaboration agreement in Japan with Nippon Kayaku for ozarelix in oncology," said Gilles Gagnon, AETerna Zentaris' President and Chief Executive Officer. "We are very pleased with these achievements which are an integral part of the Company's strategy designed to build a strong and innovative pipeline focused on oncology and endocrinology. We now look forward to continued success as we aggressively advance our lead compounds."

KEY DEVELOPMENTS FOR THE QUARTER ENDED JUNE 30, 2006

- o MARKET APPROVAL FOR CETROTIDE(R) (CETRORELIX) IN JAPAN FOR IN VITRO FERTILIZATION -- Cetrotide(R) (cetorelix) will be manufactured and marketed in Japan by AETerna Zentaris' partners Nippon Kayaku Co., Ltd. and Shionogi & Co., Ltd. with an expected launch in Japan by year-end;
- o GREEN LIGHT FROM FDA TO FILE IND TO MOVE FORWARD INTO PHASE 3 PROGRAM WITH CETRORELIX IN BPH -- The FDA reviewed the safety and efficacy data from an extensive Phase 2 program with cetorelix for the treatment of benign prostatic hyperplasia (BPH). AETerna Zentaris plans to submit an Investigational New Drug (IND) application to the FDA by year-end for the initiation of a Phase 3 program for cetorelix in BPH;

AETerna Zentaris

- o POSITIVE INTERIM PHASE 2 DATA OF PERIFOSINE IN ADVANCED RENAL CELL CARCINOMA -- Interim results of a multi-center Phase 2 trial by the Company's partner, Keryx Biopharmaceuticals, showed a 43% partial response rate;
- o POSITIVE DATA FROM ONGOING PHASE 1 TRIAL WITH AN-152 FOR GYNAECOLOGICAL AND BREAST CANCERS PRESENTED AT ASCO -- Phase 1 results for AETerna Zentaris' cytotoxic conjugate AN-152 in patients with gynaecological and breast cancers showed that the compound has a good safety profile and no dose-limiting toxicities reached so far in the selected dose levels;
- o POSITIVE IN VIVO DATA ON ZEN-019 (ORAL LHRH ANTAGONIST

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

PEPTIDOMIMETIC) PRESENTED AT ENDO 2006 -- ZEN-019 demonstrated IN VIVO activity by suppressing plasma testosterone levels. IN VIVO data showed that using ZEN-019 with a single, oral administration (20 mg/kg) in rats, led to efficient and revocable suppression of plasma testosterone levels for up to 12 hours. Furthermore, a repeat of the dosing of ZEN-019 increased the suppression time without accumulation in the plasma.

FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2006

Consolidated revenues for the quarter ended June 30, 2006 totalled \$83.4 million compared to \$60.1 million for the same period in 2005.

Consolidated Research and Development expenses, net of tax credits and grants increased to \$7.4 million for the quarter ended June 30, 2006 compared to \$6.1 million for the same period in 2005.

Consolidated selling, general and administrative expenses totalled \$15.5 million for the quarter ended June 30, 2006 compared to \$10 million for the same period in 2005.

Consolidated net loss for the quarter ended June 30, 2006 was \$1.6 million or \$0.03 per basic and diluted share compared to consolidated net earnings of \$13.3 million or \$0.28 per diluted share for the same period in 2005. Without taking into account a non-cash and non-recurring gain on dilution of investments of \$16.4 million recorded last year following the Company's subsidiary Atrium Biotechnologies' Initial Public Offering (IPO), AETerna Zentaris would have recorded a consolidated net loss of \$3.1 million or \$0.07 per basic and diluted share in the second quarter of 2005, compared to the \$1.6 million or \$0.03 per basic and diluted share consolidated net loss registered for the second quarter 2006. This \$1.5 million decrease is mainly attributable to increased net earnings of \$1.1 million from Atrium Biotechnologies and to the reduction of the operating loss from AETerna Zentaris' Biopharmaceutical segment.

Cash, cash equivalents and short-term investments reached \$47 million for the quarter ended June 30, 2006 compared to \$52.7 million as of December 31, 2005. More than \$27 million was dedicated to the Company's Biopharmaceutical segment as of June 30, 2006.

Dennis Turpin, Vice President and Chief Financial Officer of AETerna Zentaris, commented, "As we continue to successfully implement our strategy, we are pleased to maintain a sound financial position, including the ability to leverage our assets as we continue to execute our plan and

2

AETerna Zentaris

aggressively advance our pipeline. We are financially poised to continue our investment in R&D, as well as support our growing business."

DEVELOPMENTS SUBSEQUENT TO QUARTER END

- o POSITIVE PHASE 2 RESULTS FOR OZARELIX IN PROSTATE CANCER -- The study achieved its primary end-point of defining a tolerable dosage regimen of ozarelix that would ensure continuous suppression of testosterone at castration level (<0.5 ng/ml) for a three-month test period. An important secondary efficacy end-point of the study aimed at assessing tumour response as determined by a 50% or greater reduction of serum PSA levels, compared to baseline, was also

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

achieved.

- o LICENCE AND COLLABORATION AGREEMENT WITH NIPPON KAYAKU FOR OZARELIX IN ONCOLOGY -- Aeterna Zentaris granted Nippon Kayaku an exclusive license to develop and market ozarelix for all potential oncological indications in Japan.

CONFERENCE CALL INFORMATION

Management will be hosting a conference call for the investment community beginning at 11:00 a.m. Eastern Time today, Friday, August 11, to discuss 2006 second quarter financial and operating results, followed by a question and answer session.

To participate in the live conference call by telephone, please dial 800-257-3401. Individuals interested in listening to the conference call on the Internet may do so by visiting www.aeternazentaris.com. A replay will be available on the Company's Web site for 30 days.

ABOUT AETERNA ZENTARIS INC.

Aeterna Zentaris Inc. is a growing global biopharmaceutical company focused on oncology and endocrine therapy with proven expertise in drug discovery, development and commercialization.

Aeterna Zentaris also owns 48.26% of the equity of Atrium Biotechnologies Inc. (TSX: ATB) and 64.69% of its voting rights. Atrium is a developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutritional industries.

News releases and additional information are available at www.aeternazentaris.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements.

3

Aeterna Zentaris

-30-

CONTACTS

MEDIA RELATIONS
Paul Burroughs

INVESTOR RELATIONS
Jenene Thomas

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

(418) 652-8525 ext. 406
paul.burroughs@aeternazentaris.com

(418) 655-6420 or (908) 996-3154
jenene.thomas@aeternazentaris.com

ATTACHMENT: Financial summary

4

AETerna Zentaris

(IN THOUSANDS OF US DOLLARS, EXCEPT SHARE
AND PER SHARE DATA)

CONSOLIDATED RESULTS UNAUDITED	QUARTERS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2006	2005	2006	2005
	\$	\$	\$	\$
REVENUES	83,390	60,144	167,867	122,009
OPERATING EXPENSES				
Cost of sales	52,619	38,564	109,815	75,727
Selling, general and administrative	15,517	10,014	29,084	19,949
R&D costs, net of tax credits and grants	7,380	6,099	14,281	12,545
Depreciation and amortization	2,478	2,011	4,859	3,829
	77,994	56,689	158,039	112,050
EARNINGS FROM OPERATIONS	5,396	3,456	9,828	9,959
Interest income	455	426	875	732
Interest expense	(2,004)	(2,668)	(5,227)	(4,826)
Foreign exchange gain (loss)	(295)	(155)	(83)	53
EARNINGS BEFORE THE FOLLOWING ITEMS	3,552	1,059	5,393	5,918
Current income taxes	(2,395)	(2,131)	(4,391)	(4,252)
Future income taxes	630	(65)	1,819	(1,162)
Gain (loss) on dilution of investments	(81)	16,393	(135)	16,393
Non-controlling interest	(3,268)	(1,980)	(6,828)	(3,503)
NET EARNINGS (LOSS) FOR THE PERIOD	(1,562)	13,276	(4,142)	13,394
NET EARNINGS (LOSS) PER SHARE				
Basic	(0.03)	0.29	(0.08)	0.29
Diluted	(0.03)	0.28	(0.08)	0.28
Weighted average number of shares				
Basic	52,682,969	46,139,814	52,098,592	46,139,814

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Diluted	53,261,928	46,448,125	52,651,808	46,506,728
Issued and outstanding shares				53,160,970

5

AETerna Zentaris

BIOPHARMACEUTICAL SEGMENT -- SELECTED FINANCIAL INFORMATION
(IN THOUSANDS OF US DOLLARS)

UNAUDITED	QUARTERS ENDED JUNE 30,		SIX MONTHS ENDED JUNE 30,	
	2006	2005	2006	2005
	\$	\$	\$	\$
REVENUES				
Sales and royalties	5,228	5,381	11,803	12,279
License fees	4,155	4,779	6,328	11,628
	9,383	10,160	18,131	23,907
=====				
COST OF SALES	1,404	1,835	4,045	4,169
SELLING AND ADMINISTRATIVE	4,515	3,907	8,360	7,285
R&D EXPENSE, NET OF TAX				
CREDITS AND GRANTS	7,262	6,081	14,066	12,431
DEPRECIATION AND AMORTIZATION	1,653	1,708	3,216	3,258
	14,834	13,531	29,687	27,143
=====				
LOSS FROM OPERATIONS	(5,451)	(3,371)	(11,556)	(3,236)
=====				
CASH FLOWS GENERATED (USED)				
BY OPERATING ACTIVITIES	(3,518)	1,076	(7,042)	247
=====				

UNAUDITED	AS AT	As at
	JUNE 30, 2006	December 31, 2005
	\$	\$
Cash and short-term investments	47,041	52,705
Other current assets	111,178	110,971
	158,219	163,676
Long-term assets	277,404	263,835
	435,623	427,511
Total assets	435,623	427,511
=====		

Edgar Filing: Aeterna Zentaris Inc. - Form 6-K

Current liabilities	62,378	64,174
Long-term debt	100,706	135,743
Other long-term liabilities	54,423	53,532
Non-controlling interest	74,760	64,531
	-----	-----
	292,267	317,980
Shareholders' equity	143,356	109,531
	-----	-----
Total liabilities and shareholders' equity	435,623	427,511
	=====	=====

6

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AETERNA ZENTARIS INC.

Date: August 14, 2006

By: /s/ Mario Paradis

 Mario Paradis
 Vice President, Finance, Administration
 and Corporate Secretary